Measles vaccination coverage estimates from surveys, clinic records, and immune markers in oral fluid and blood: A population-based cross-sectional study

Kyla Hayford, Mohammed S. Shomik, Hassan M. Al-Emran, William J Moss, David M Bishai, Orin S. Levine

Research output: Contribution to journalArticle

Abstract

Background: Recent outbreaks of measles and polio in low-income countries illustrate that conventional methods for estimating vaccination coverage do not adequately identify susceptible children. Immune markers of protection against vaccine-preventable diseases in oral fluid (OF) or blood may generate more accurate measures of effective vaccination history, but questions remain about whether antibody surveys are feasible and informative tools for monitoring immunization program performance compared to conventional vaccination coverage indicators. This study compares six indicators of measles vaccination status, including immune markers in oral fluid and blood, from children in rural Bangladesh and evaluates the implications of using each indicator to estimate measles vaccination coverage. Methods. A cross-sectional population-based study of children ages 12-16 months in Mirzapur, Bangladesh, ascertained measles vaccination (MCV1) history from conventional indicators: maternal report, vaccination card records, 'card + history' and EPI clinic records. Oral fluid from all participants (n = 1226) and blood from a subset (n = 342) were tested for measles IgG antibodies as indicators of MCV1 history and compared to conventional MCV1 coverage indicators. Results: Maternal report yielded the highest MCV1 coverage estimates (90.8%), followed by EPI records (88.6%), and card + history (84.2%). Seroprotection against measles by OF (57.3%) was significantly lower than other indicators, even after adjusting for incomplete seroconversion and assay performance (71.5%). Among children with blood results, 88.6% were seroprotected, which was significantly higher than coverage by card + history and OF serostatus but consistent with coverage by maternal report and EPI records. Children with vaccination cards or EPI records were more likely to have a history of receiving MCV1 than those without cards or records. Despite similar MCV1 coverage estimates across most indicators, within-child agreement was poor for all indicators. Conclusions: Measles IgG antibodies in OF was not a suitable immune marker for monitoring measles vaccination coverage in this setting. Because agreement between conventional MCV1 indicators was mediocre, immune marker surveillance with blood samples could be used to validate conventional MCV1 indicators and generate adjusted results that can be compared across indicators.

Original languageEnglish (US)
Article number1211
JournalBMC Public Health
Volume13
Issue number1
DOIs
StatePublished - Dec 20 2013

Fingerprint

Measles
Vaccination
Cross-Sectional Studies
Biomarkers
Population
History
Bangladesh
Mothers
Antibodies
Immunoglobulin G
Surveys and Questionnaires
Immunologic Monitoring
Immunization Programs
Poliomyelitis
Disease Outbreaks
Vaccines
Interviews

Keywords

  • Bangladesh
  • Immune marker
  • Immunization
  • Maternal report
  • Measles
  • Oral fluid
  • Surveillance
  • Vaccination
  • Vaccination card

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Measles vaccination coverage estimates from surveys, clinic records, and immune markers in oral fluid and blood : A population-based cross-sectional study. / Hayford, Kyla; Shomik, Mohammed S.; Al-Emran, Hassan M.; Moss, William J; Bishai, David M; Levine, Orin S.

In: BMC Public Health, Vol. 13, No. 1, 1211, 20.12.2013.

Research output: Contribution to journalArticle

@article{a0822dcb64a84091b86c751543e938cd,
title = "Measles vaccination coverage estimates from surveys, clinic records, and immune markers in oral fluid and blood: A population-based cross-sectional study",
abstract = "Background: Recent outbreaks of measles and polio in low-income countries illustrate that conventional methods for estimating vaccination coverage do not adequately identify susceptible children. Immune markers of protection against vaccine-preventable diseases in oral fluid (OF) or blood may generate more accurate measures of effective vaccination history, but questions remain about whether antibody surveys are feasible and informative tools for monitoring immunization program performance compared to conventional vaccination coverage indicators. This study compares six indicators of measles vaccination status, including immune markers in oral fluid and blood, from children in rural Bangladesh and evaluates the implications of using each indicator to estimate measles vaccination coverage. Methods. A cross-sectional population-based study of children ages 12-16 months in Mirzapur, Bangladesh, ascertained measles vaccination (MCV1) history from conventional indicators: maternal report, vaccination card records, 'card + history' and EPI clinic records. Oral fluid from all participants (n = 1226) and blood from a subset (n = 342) were tested for measles IgG antibodies as indicators of MCV1 history and compared to conventional MCV1 coverage indicators. Results: Maternal report yielded the highest MCV1 coverage estimates (90.8{\%}), followed by EPI records (88.6{\%}), and card + history (84.2{\%}). Seroprotection against measles by OF (57.3{\%}) was significantly lower than other indicators, even after adjusting for incomplete seroconversion and assay performance (71.5{\%}). Among children with blood results, 88.6{\%} were seroprotected, which was significantly higher than coverage by card + history and OF serostatus but consistent with coverage by maternal report and EPI records. Children with vaccination cards or EPI records were more likely to have a history of receiving MCV1 than those without cards or records. Despite similar MCV1 coverage estimates across most indicators, within-child agreement was poor for all indicators. Conclusions: Measles IgG antibodies in OF was not a suitable immune marker for monitoring measles vaccination coverage in this setting. Because agreement between conventional MCV1 indicators was mediocre, immune marker surveillance with blood samples could be used to validate conventional MCV1 indicators and generate adjusted results that can be compared across indicators.",
keywords = "Bangladesh, Immune marker, Immunization, Maternal report, Measles, Oral fluid, Surveillance, Vaccination, Vaccination card",
author = "Kyla Hayford and Shomik, {Mohammed S.} and Al-Emran, {Hassan M.} and Moss, {William J} and Bishai, {David M} and Levine, {Orin S.}",
year = "2013",
month = "12",
day = "20",
doi = "10.1186/1471-2458-13-1211",
language = "English (US)",
volume = "13",
journal = "BMC Public Health",
issn = "1471-2458",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Measles vaccination coverage estimates from surveys, clinic records, and immune markers in oral fluid and blood

T2 - A population-based cross-sectional study

AU - Hayford, Kyla

AU - Shomik, Mohammed S.

AU - Al-Emran, Hassan M.

AU - Moss, William J

AU - Bishai, David M

AU - Levine, Orin S.

PY - 2013/12/20

Y1 - 2013/12/20

N2 - Background: Recent outbreaks of measles and polio in low-income countries illustrate that conventional methods for estimating vaccination coverage do not adequately identify susceptible children. Immune markers of protection against vaccine-preventable diseases in oral fluid (OF) or blood may generate more accurate measures of effective vaccination history, but questions remain about whether antibody surveys are feasible and informative tools for monitoring immunization program performance compared to conventional vaccination coverage indicators. This study compares six indicators of measles vaccination status, including immune markers in oral fluid and blood, from children in rural Bangladesh and evaluates the implications of using each indicator to estimate measles vaccination coverage. Methods. A cross-sectional population-based study of children ages 12-16 months in Mirzapur, Bangladesh, ascertained measles vaccination (MCV1) history from conventional indicators: maternal report, vaccination card records, 'card + history' and EPI clinic records. Oral fluid from all participants (n = 1226) and blood from a subset (n = 342) were tested for measles IgG antibodies as indicators of MCV1 history and compared to conventional MCV1 coverage indicators. Results: Maternal report yielded the highest MCV1 coverage estimates (90.8%), followed by EPI records (88.6%), and card + history (84.2%). Seroprotection against measles by OF (57.3%) was significantly lower than other indicators, even after adjusting for incomplete seroconversion and assay performance (71.5%). Among children with blood results, 88.6% were seroprotected, which was significantly higher than coverage by card + history and OF serostatus but consistent with coverage by maternal report and EPI records. Children with vaccination cards or EPI records were more likely to have a history of receiving MCV1 than those without cards or records. Despite similar MCV1 coverage estimates across most indicators, within-child agreement was poor for all indicators. Conclusions: Measles IgG antibodies in OF was not a suitable immune marker for monitoring measles vaccination coverage in this setting. Because agreement between conventional MCV1 indicators was mediocre, immune marker surveillance with blood samples could be used to validate conventional MCV1 indicators and generate adjusted results that can be compared across indicators.

AB - Background: Recent outbreaks of measles and polio in low-income countries illustrate that conventional methods for estimating vaccination coverage do not adequately identify susceptible children. Immune markers of protection against vaccine-preventable diseases in oral fluid (OF) or blood may generate more accurate measures of effective vaccination history, but questions remain about whether antibody surveys are feasible and informative tools for monitoring immunization program performance compared to conventional vaccination coverage indicators. This study compares six indicators of measles vaccination status, including immune markers in oral fluid and blood, from children in rural Bangladesh and evaluates the implications of using each indicator to estimate measles vaccination coverage. Methods. A cross-sectional population-based study of children ages 12-16 months in Mirzapur, Bangladesh, ascertained measles vaccination (MCV1) history from conventional indicators: maternal report, vaccination card records, 'card + history' and EPI clinic records. Oral fluid from all participants (n = 1226) and blood from a subset (n = 342) were tested for measles IgG antibodies as indicators of MCV1 history and compared to conventional MCV1 coverage indicators. Results: Maternal report yielded the highest MCV1 coverage estimates (90.8%), followed by EPI records (88.6%), and card + history (84.2%). Seroprotection against measles by OF (57.3%) was significantly lower than other indicators, even after adjusting for incomplete seroconversion and assay performance (71.5%). Among children with blood results, 88.6% were seroprotected, which was significantly higher than coverage by card + history and OF serostatus but consistent with coverage by maternal report and EPI records. Children with vaccination cards or EPI records were more likely to have a history of receiving MCV1 than those without cards or records. Despite similar MCV1 coverage estimates across most indicators, within-child agreement was poor for all indicators. Conclusions: Measles IgG antibodies in OF was not a suitable immune marker for monitoring measles vaccination coverage in this setting. Because agreement between conventional MCV1 indicators was mediocre, immune marker surveillance with blood samples could be used to validate conventional MCV1 indicators and generate adjusted results that can be compared across indicators.

KW - Bangladesh

KW - Immune marker

KW - Immunization

KW - Maternal report

KW - Measles

KW - Oral fluid

KW - Surveillance

KW - Vaccination

KW - Vaccination card

UR - http://www.scopus.com/inward/record.url?scp=84890537190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890537190&partnerID=8YFLogxK

U2 - 10.1186/1471-2458-13-1211

DO - 10.1186/1471-2458-13-1211

M3 - Article

C2 - 24359402

AN - SCOPUS:84890537190

VL - 13

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

IS - 1

M1 - 1211

ER -